Orphanet Journal of Rare Diseases | Defining the Therapeutic Corridor of Stability in Enzyme Replacement Therapy for Pompe Disease

Recommend:

This study provides a multidimensional stability assessment framework for long-term enzyme replacement therapy (ERT) in Pompe disease, offering direct guidance for clinical monitoring and individualized treatment decisions.

 

Literature Overview

The article titled 'Defining the therapeutic corridor of stability in enzyme replacement therapy for Pompe disease: a position statement,' published in the Orphanet Journal of Rare Diseases, systematically explores how to quantitatively assess whether patients with Pompe disease remain in a stable therapeutic state under enzyme replacement therapy (ERT). The authors integrated data from Phase II and III randomized controlled trials, open-label extension studies, registry studies, real-world evidence, and consensus recommendations to propose a multidimensional 'therapeutic corridor of stability' framework encompassing respiratory function, motor performance, and biomarkers. This framework aims to help clinicians identify when patients deviate from stability, prompting re-evaluation, escalation, or switching of therapy. The article emphasizes that with the emergence of next-generation ERT drugs (e.g., avalglucosidase alfa and cipaglucosidase alfa + miglustat), treatment decisions have shifted from 'whether to treat' to 'whether the current treatment remains effective,' necessitating standardized monitoring strategies.

Background Knowledge

Pompe disease, also known as glycogen storage disease type II, is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GAA gene, leading to deficiency of acid alpha-glucosidase (GAA enzyme) and subsequent glycogen accumulation in skeletal, respiratory, and cardiac muscles. The disease exhibits a broad clinical spectrum, ranging from rapidly progressive, fatal infantile cardiomyopathy to slowly progressive adult-onset muscle weakness and respiratory failure.

Currently, enzyme replacement therapy (ERT) is the primary treatment. However, first-generation ERT (alglucosidase alfa) suffers from low cellular uptake efficiency, high immunogenicity, and waning long-term efficacy. Next-generation ERTs improve lysosomal targeting and enzyme stability by optimizing the M6P modification of GAA enzyme (e.g., avalglucosidase alfa) or combining with pharmacological chaperones (e.g., cipaglucosidase alfa + miglustat), demonstrating superior biomarker suppression and functional stabilization.

Nonetheless, clinical practice lacks consensus on quantitative criteria to define ERT treatment failure or the need for therapy switch. Existing guidelines (e.g., EPOC’s 'start-switch-stop') provide decision frameworks but do not define specific thresholds. Moreover, global diagnostic and epidemiological heterogeneity, high inter-individual variability, and measurement errors in respiratory and functional metrics complicate treatment monitoring. Therefore, an actionable 'therapeutic corridor of stability' based on multisource evidence is urgently needed to guide individualized management.

 

Assess the pathogenicity of gene variants to provide a reference for analyzing the functional impact of [[GAA]] gene mutations associated with Pompe disease.

Learn More

 

Methods and Core Experiments

The authors employed a structured evidence synthesis approach, systematically reviewing key clinical trials (LOTS, COMET, PROPEL), long-term extension studies (COMET OLE, ATB200-07), real-world cohorts (STIG, Mendelsohn et al.), the International Pompe Registry (IPR), EPOC consensus, and scoping reviews. The study focused on late-onset Pompe disease (LOPD), evaluating multiple efficacy domains including forced vital capacity (FVC), 6-minute walk test (6MWT), urinary glucotetraose (Hex4), serum creatine kinase (CK), respiratory muscle strength, anti-drug antibody titers, functional scores, and patient-reported outcomes (PROs).

Key evidence came from the COMET trial, showing that avalglucosidase alfa significantly outperformed alglucosidase alfa in FVC improvement at 49 weeks (+2.89% vs. +0.46%), with sustained stability at 97 and 145 weeks in extension studies. The PROPEL trial demonstrated that cipaglucosidase alfa + miglustat resulted in significantly less FVC decline at 52 weeks compared to control (-0.9% vs. -4.0%), along with greater improvement in 6MWT. Real-world studies (e.g., STIG) revealed secondary functional decline after long-term alglucosidase alfa treatment, with FVC decreasing by an average of 14.93% over 10 years, defining the lower boundary of treatment failure. Multicenter real-world switching studies (e.g., Mendelsohn et al.) confirmed that ERT switching is widely feasible in LOPD patients and associated with clinical stability, supporting the clinical applicability of the 'stability corridor'.

Key Conclusions and Perspectives

• An annual FVC change between approximately -1% and +5% is proposed as the respiratory stability corridor. A confirmed FVC decline >5% within 12 months constitutes a warning threshold, indicating the need for therapy re-evaluation. This threshold is based on data from LOTS, COMET, and STIG cohorts, providing direct guidance for GAA-related respiratory function monitoring.
• 6MWT changes within ±25m from peak are considered stable. A confirmed decline >25m from peak is an actionable threshold. This standard integrates absolute improvement values from LOTS and COMET trials (+25.1m, +32m), accounts for individual baseline and peak values, and applies to assessing response to GAA-targeted therapy.
• Next-generation ERT can significantly reduce or normalize urinary Hex4 and serum CK levels, serving as surrogate markers for early lysosomal glycogen clearance. Sustained elevation or increasing trends should prompt evaluation of adherence, infusion adequacy, immunogenicity, or efficacy, providing important insights into GAA-targeted therapeutic mechanisms.
• An anti-drug antibody titer ≥1:12,800 with persistent increase, especially when accompanied by functional or biomarker deterioration, should trigger immunogenicity assessment and potential therapy switch. This threshold is based on Pompe disease literature consensus and provides a reference for monitoring immunogenic risk in GAA protein therapies.
• Treatment decisions should be based on confirmed decline across multiple domains, not isolated metrics. Structured monitoring every 6 months, integrating function, respiration, biomarkers, and patient-reported outcomes, is recommended to support multidisciplinary, individualized long-term care for Pompe disease.

Research Significance and Outlook

This study establishes the first quantitative stability framework for long-term ERT management in Pompe disease based on multisource evidence, filling a critical gap in clinical decision-making tools. It not only facilitates early detection of treatment failure but also provides reference standards for future trial designs (e.g., endpoint definitions in switch studies). The framework emphasizes individualized monitoring and multidimensional assessment, advancing Pompe disease management from a one-size-fits-all approach toward precision medicine.

Future work should prospectively validate the predictive value of this 'stability corridor' in multicenter cohorts—specifically, whether patients who deviate from the corridor can regain stability by switching to next-generation ERT. Furthermore, as novel strategies such as gene therapy and substrate reduction therapy emerge, the framework must be expanded to accommodate different response patterns (e.g., delayed stabilization, biochemical improvement preceding functional gains).

 

Input genes related to Pompe disease to view their associated signaling pathways and known upstream and downstream molecules, helping to understand the impact of [[GAA]] enzyme deficiency on cellular metabolic pathways.

Learn More

 

Conclusion

The 'therapeutic corridor of stability' proposed in this study represents a significant milestone in the long-term management of enzyme replacement therapy for Pompe disease. It transforms complex, multidimensional clinical data into actionable quantitative standards, providing clinicians with a structured tool to identify treatment failure and guide therapy switching. The framework not only integrates the best available evidence but also emphasizes individualized, multidisciplinary, and patient-centered care, helping to optimize long-term outcomes for Pompe disease patients. From bench to bedside, this study sets a benchmark for dynamic monitoring and precision intervention in rare disease treatment, with its methodology extendable to the long-term management of other lysosomal storage disorders. As more real-world data accumulate and novel therapies emerge, this corridor framework will become a cornerstone of Pompe disease care, driving continuous progress from 'treatment' to 'control' and ultimately to 'improved quality of life.' Future efforts should focus on prospective validation and dynamic updates of the framework to adapt to an evolving treatment landscape.

 

Benedikt Schoser. Defining the therapeutic corridor of stability in enzyme replacement therapy for Pompe disease: a position statement. Orphanet Journal of Rare Diseases.